Tracking cancer DNA in blood to detect early return of breast cancer
Part of Cancer, Skin clinical trials.
This study tracks tiny traces of cancer DNA in the blood over time to see if it can find early signs of breast cancer coming back. It looks at different types of breast cancer and at different points in a patient's treatment journey.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with breast cancer.
- You must be willing to give blood or tissue samples for research.
- Depending on your situation, you should be in one of these stages: newly diagnosed before surgery, or after surgery with no signs of cancer, or more than 5 years since diagnosis with no signs of cancer.
- If your cancer is HR+, HER2-, it must be considered high risk (like having at least 4 positive lymph nodes, or 1-3 positive nodes with a large tumor or high grade).
- You cannot have another active cancer, or have had a different cancer (except non-invasive breast changes) within the last 3 years.
- Your treatment must be aimed at curing the cancer (not just managing it).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
This trial uses a blood test to look for tiny bits of tumor DNA after treatment. If found, participants receive new drug combinations to try to prevent cancer from returning.
This trial checks whether specific “surveillance” markers (measured from blood and bone marrow) can help predict if breast cancer comes back after standard treatments. It may help doctors monitor you more accurately and earlier if recurrence risk is high.
This trial is testing whether checking DNA from your blood (circulating tumor DNA) can help doctors choose the best neoadjuvant (pre-surgery) treatment for HER2-positive or triple-negative breast cancer. It aims to personalize therapy based on how your tumor responds.
This trial uses a simple blood test to look for leftover cancer DNA in people with triple-negative breast cancer who still have disease after chemotherapy and surgery. It aims to catch any early signs of the cancer coming back.
This study looks for tiny bits of cancer DNA in your blood after breast cancer surgery. A blood test called NGS may help doctors find early signs of cancer coming back, and you would give samples and have checkups for 3 years.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.